---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058194"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:35:25.571415+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TScan reports Q1 2024 results: net loss $30.1M, first solid tumor patient dosed, heme patients relapse-free

## Summary
- Net loss of $30.1M for Q1 2024 compared to $22.6M in Q1 2023; revenue fell to $0.6M from $6.8M.
- First patient dosed in Phase 1 solid tumor trial with TSC-203-A0201 targeting PRAME; initial data expected H2 2024.
- All eight heme treatment-arm patients relapse-free with median follow-up >10 months; two control patients relapsed.
- Closed upsized $167.8M public offering in April; cash and marketable securities $162.8M at March 31, extending runway to Q4 2026.

## SEC filing metadata
- accession: 0000950170-24-058194
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017024058194/0000950170-24-058194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017024058194/tcrx-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058194
- JSON: https://secwatch.observer/filing/0000950170-24-058194.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058194.txt

## Key facts
- Earnings Releases
  TScan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $0.6 million
  - Result: reported results
  source text: • Long-term duration of response data for multiplex therapy anticipated in 2025. First Quarter 2024 Financial Results Revenue: Revenue for the first quarter of 2024 was $0.6 million, compared to $6.8 million for the first quarter of 2023. The decrease was primarily due to the timing of research activities pursuant to the Company’s collaboration agreements.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000095017024058194/0000950170-24-058194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.